JP2021503501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503501A5 JP2021503501A5 JP2020545072A JP2020545072A JP2021503501A5 JP 2021503501 A5 JP2021503501 A5 JP 2021503501A5 JP 2020545072 A JP2020545072 A JP 2020545072A JP 2020545072 A JP2020545072 A JP 2020545072A JP 2021503501 A5 JP2021503501 A5 JP 2021503501A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- halogen
- compound according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 108
- 125000000217 alkyl group Chemical group 0.000 claims description 93
- 229910052736 halogen Inorganic materials 0.000 claims description 34
- 150000002367 halogens Chemical group 0.000 claims description 33
- 150000002148 esters Chemical class 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 125000000304 alkynyl group Chemical group 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 230000003831 deregulation Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 230000006662 intracellular pathway Effects 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- -1 cyclopentynyl Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 150000001345 alkine derivatives Chemical class 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000000034 method Methods 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 0 C*(C)(C)c(cc1)cc(N(CC([N+]([O-])=O)=*)c(c2ccc3Cl)c3OC(*)=C)c1C2=O Chemical compound C*(C)(C)c(cc1)cc(N(CC([N+]([O-])=O)=*)c(c2ccc3Cl)c3OC(*)=C)c1C2=O 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762588820P | 2017-11-20 | 2017-11-20 | |
| US62/588,820 | 2017-11-20 | ||
| US201862631530P | 2018-02-16 | 2018-02-16 | |
| US62/631,530 | 2018-02-16 | ||
| US201862723660P | 2018-08-28 | 2018-08-28 | |
| US62/723,660 | 2018-08-28 | ||
| PCT/US2018/062021 WO2019100061A1 (en) | 2017-11-20 | 2018-11-20 | Oxoacridinyl acetic acid derivatives and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503501A JP2021503501A (ja) | 2021-02-12 |
| JP2021503501A5 true JP2021503501A5 (https=) | 2022-01-06 |
| JP7323539B2 JP7323539B2 (ja) | 2023-08-08 |
Family
ID=66540425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545072A Active JP7323539B2 (ja) | 2017-11-20 | 2018-11-20 | オキソアクリジニル酢酸誘導体および使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10745358B2 (https=) |
| EP (1) | EP3713920A4 (https=) |
| JP (1) | JP7323539B2 (https=) |
| KR (1) | KR20200100081A (https=) |
| CN (1) | CN111630036B (https=) |
| AU (1) | AU2018368789B2 (https=) |
| BR (1) | BR112020009592A2 (https=) |
| CA (1) | CA3079262A1 (https=) |
| IL (1) | IL274796A (https=) |
| MX (1) | MX2020004902A (https=) |
| PH (1) | PH12020550652A1 (https=) |
| SG (1) | SG11202004442VA (https=) |
| WO (1) | WO2019100061A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7270608B2 (ja) | 2017-08-31 | 2023-05-10 | エフ－スター・セラピューティクス・インコーポレイテッド | 化合物、組成物、及び疾患の治療方法 |
| US20220227761A1 (en) * | 2019-05-16 | 2022-07-21 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| WO2020249773A1 (en) * | 2019-06-12 | 2020-12-17 | Ryvu Therapeutics S.A. | Next-generation modulators of stimulator of interferon genes (sting) |
| CN112442033A (zh) * | 2019-08-28 | 2021-03-05 | 迈德欣国际有限公司 | Sting通路调节剂及其用途 |
| CN112624972A (zh) * | 2019-09-24 | 2021-04-09 | 中国人民解放军军事科学院军事医学研究院 | 吖啶酮类化合物及医药用途 |
| RU2730530C1 (ru) * | 2019-10-29 | 2020-08-24 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Новое химическое соединение L-лизина 9-оксоакридинил-10-ацетат, стимулирующее продукцию интерлейкина-24 и фактора некроза опухолей - бета |
| CN112778336B (zh) * | 2019-11-02 | 2023-05-05 | 上海凌达生物医药有限公司 | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 |
| CN111039849B (zh) * | 2019-12-26 | 2021-07-06 | 阜阳欣奕华材料科技有限公司 | 一种含有咔唑环类化合物的制备方法 |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681360A (en) | 1971-04-09 | 1972-08-01 | Hoffmann La Roche | Antiviral substituted acridanones |
| JPH0867873A (ja) | 1994-08-29 | 1996-03-12 | Pioneer Electron Corp | 有機エレクトロルミネッセンス素子 |
| PL322083A1 (en) | 1995-03-02 | 1998-01-05 | Yamanouchi Pharma Co Ltd | Novel derivative of quinuklidine, incorporating a tricyclic system of condensed heteronuclei |
| AU7145396A (en) | 1995-10-04 | 1997-04-28 | Eisai Co. Ltd. | Acridone compounds |
| US6333322B1 (en) * | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| RU2118532C1 (ru) * | 1996-04-10 | 1998-09-10 | Олег Викторович Травкин | Противоинфекционное, противовоспалительное и противоопухолевое лекарственное средство |
| JPH11100373A (ja) * | 1997-09-26 | 1999-04-13 | Eisai Co Ltd | 新規フェノチアジン誘導体及びその医薬 |
| RU2197248C2 (ru) * | 2001-03-20 | 2003-01-27 | Травкин Олег Викторович | Лекарственный препарат, обладающий иммуномоделирующим, иммунокоррегирующим, противопаразитарным, противосклеротическим, противовирусным, противобактериальным, противогрибковым, противовоспалительным и противоопухолевым действием, и способ его приготовления |
| GB0113435D0 (en) | 2001-06-04 | 2001-07-25 | Amersham Pharm Biotech Uk Ltd | Acridone derivatives as labels for fluorescence detection of target materials |
| GB0113434D0 (en) | 2001-06-04 | 2001-07-25 | Amersham Pharm Biotech Uk Ltd | Quinacridone derivatives as labels for fluorescence detection of biological materials |
| WO2004106923A1 (en) | 2003-05-28 | 2004-12-09 | Amersham Biosciences Uk Limited | Differential analysis of cell surface proteins on closed membrane structures by labelling with dyes in the presence of an internal standard |
| WO2005099656A2 (en) * | 2004-04-06 | 2005-10-27 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| JP2006004736A (ja) | 2004-06-17 | 2006-01-05 | Sumitomo Chemical Co Ltd | 光電変換素子及び光電変換素子用色素 |
| WO2008021745A2 (en) | 2006-08-16 | 2008-02-21 | Itherx Pharmaceuticals, Inc. | Hepatitis c virus entry inhibitors |
| JP2008090130A (ja) | 2006-10-04 | 2008-04-17 | Konica Minolta Medical & Graphic Inc | 感光性平版印刷版材料 |
| WO2009112791A1 (en) | 2008-03-14 | 2009-09-17 | Assaymetrics Limited | Fluorogenic peptides and their method of production |
| JP2009271403A (ja) | 2008-05-09 | 2009-11-19 | Konica Minolta Medical & Graphic Inc | 感光性平版印刷版材料および平版印刷版の製造方法 |
| JP5717959B2 (ja) | 2009-11-17 | 2015-05-13 | 株式会社Adeka | 芳香族スルホニウム塩化合物 |
| US8618125B2 (en) | 2011-01-14 | 2013-12-31 | Heptiva LLC | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance |
| WO2013022740A2 (en) | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
| WO2015046502A1 (ja) | 2013-09-30 | 2015-04-02 | 富士フイルム株式会社 | 感光性樹脂組成物、硬化膜の製造方法、硬化膜、有機ｅｌ表示装置および液晶表示装置 |
| CN109394752A (zh) * | 2013-10-21 | 2019-03-01 | 德雷克塞尔大学 | 治疗慢性乙型肝炎病毒感染的sting激动剂的用途 |
| CN103709122B (zh) | 2013-11-29 | 2016-05-25 | 四川大学 | 用于治疗的抗肿瘤和抗真菌化合物 |
| WO2016179702A1 (en) * | 2015-05-11 | 2016-11-17 | Ranju Ralhan | Acridinone compositions for treating head and neck cancers and methods of prognosing head and neck cancers |
| WO2018165494A1 (en) | 2017-03-10 | 2018-09-13 | Albert Einstein College Of Medicine, Inc. | Small molecule bax inhibitors and uses thereof |
-
2018
- 2018-11-20 SG SG11202004442VA patent/SG11202004442VA/en unknown
- 2018-11-20 CA CA3079262A patent/CA3079262A1/en active Pending
- 2018-11-20 MX MX2020004902A patent/MX2020004902A/es unknown
- 2018-11-20 AU AU2018368789A patent/AU2018368789B2/en not_active Ceased
- 2018-11-20 BR BR112020009592-3A patent/BR112020009592A2/pt not_active IP Right Cessation
- 2018-11-20 US US16/195,997 patent/US10745358B2/en active Active
- 2018-11-20 WO PCT/US2018/062021 patent/WO2019100061A1/en not_active Ceased
- 2018-11-20 KR KR1020207017927A patent/KR20200100081A/ko not_active Ceased
- 2018-11-20 JP JP2020545072A patent/JP7323539B2/ja active Active
- 2018-11-20 EP EP18878928.3A patent/EP3713920A4/en active Pending
- 2018-11-20 CN CN201880086600.0A patent/CN111630036B/zh active Active
-
2020
- 2020-05-15 PH PH12020550652A patent/PH12020550652A1/en unknown
- 2020-05-20 IL IL274796A patent/IL274796A/en unknown
-
2022
- 2022-07-28 US US17/875,770 patent/US20230113570A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503501A5 (https=) | ||
| RU2704129C2 (ru) | Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения | |
| JP2019507114A5 (https=) | ||
| JP2020510091A5 (https=) | ||
| JP7026787B2 (ja) | ヒストン脱アセチル化酵素１および／または２（ｈｄａｃ１－２）の選択的阻害剤としての新規なヘテロアリールアミド誘導体 | |
| JP2020530838A5 (https=) | ||
| JP2018536634A5 (https=) | ||
| JP2017518981A5 (https=) | ||
| JP2018522879A5 (https=) | ||
| JP2020514316A5 (https=) | ||
| EP3215155A1 (en) | Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase | |
| JP2003501420A5 (https=) | ||
| JP2007529421A5 (https=) | ||
| KR20160140892A (ko) | 의약에 사용하기 위한 인돌 유도체 | |
| JP2019510810A5 (https=) | ||
| JP2017537948A5 (https=) | ||
| JP2016526540A5 (https=) | ||
| JP2001526269A (ja) | アリール及びヘテロアリール置換複素環式尿素を用いたｒａｆキナーゼの阻害 | |
| JP2009513703A5 (https=) | ||
| JP2013515074A5 (https=) | ||
| EA020749B1 (ru) | Вич-ингибирующие 5,6-замещенные пиримидины | |
| FI3959211T3 (fi) | 4h-pyrrolo[3,2-c]pyridin-4-oniyhdisteitä | |
| JP2020506951A5 (https=) | ||
| SI3009431T1 (en) | 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer | |
| JP2013503903A5 (https=) |